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Abstract
Background: Effects of androgens on follicle maturation have been controversial for some time. Here, we review
the potential of their applications in improving human ovulation induction, based on human and animal data,
reported in the literature.
Methods: We reviewed the published literature for the years 2005-2011, using relevant key words, in PubMed,
Medline and Cochrane reviews, and then performed secondary reviews of referenced articles, which previously had
not been known or preceded the searched time period. A total of 217 publications were reviewed.
Results: Contrary to widely held opinion, recent data, mostly developed in the mouse, convincingly demonstrate
essential contribution of androgens to normal follicle maturation and, therefore, female fertility. Androgens appear
most engaged at preantral and antral stages, primarily affect granulosa cells, and exert effects via androgen
receptors (AR) through transcriptional regulation but also in non-genomic ways, with ligand-activated AR
modulating follicle stimulating hormone (FSH) activity in granulosa cells. While some androgens, like testosterone
(T) and dehydroepiandrosterone (DHEA), appear effective in improving functional ovarian reserve (FOR) in women
with diminished ovarian reserve (DOR), others may even exert opposite effects. Such differences in androgens may,
at least partially, reflect different levels of agonism to AR.
Discussion: Selective androgens appear capable of improving early stages of folliculogenesis. They, therefore, may
represent forerunners of a completely new class of ovulation-inducing medications, which, in contrast to
gonadotropins, affect follicle maturation at much earlier stages.
Background
Understanding of effects of androgens on follicle
maturation and ovulation induction has recently under-
gone considerable change. Primarily because of reported
negative effects in mouse models [1-4], androgens, for
the longest time, almost universally were considered
detrimental to normal folliculogenesis. Poor oocyte qual-
ity observed in human hyperandrogenic polycystic ovary
syndrome (PCOS) contributed to this opinion [5]. Some
recent mouse studies also still emphasize adverse andro-
gen effects on oocyte meiotic capacity above certain
concentrations [6].
The picture now evolving, based on androgen receptor
(AR) studies in the mouse [7,8], is, however, more com-
plex and potentially reflects substantial theoretical and
practical relevance to therapeutic ovulation induction in
humans. We, here, therefore, present a literature review
on the subject, primarily concentrating on developments
after 2007, the cut off date of a review on the subject by
Laufer, published in 2009 [9].
Literature search strategy
We performed a literature search of PubMed, Medline
and Cochrane reviews for the years 2005-2011 under
the following key phrases/words: < androgens/testoster-
one (T)/androstenedione (ASD)/dehydroepiandrosterone
(DHEA)/aromatase inhibitors (AI) in spontaneous ovula-
tion>, < androgens/T/ASD/DHEA/AI in ovulation
induction>, < androgens/T/ASD/DHEA/AI in
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cle maturation>, < androgens/T/ASD/DHEA/AI and
meiosis>, < androgens/T/ASD/DHEA/AI and aneu-
ploidy>, < androgens/T/ASD/DHEA/AI in infertility> <
androgens/T/ASD/DHEA/AI in in vitro fertilization
(IVF)>, < androgens/T/ASD/DHEA/AI in diminished
ovarian reserve (DOR)>, < androgens/T/ASD/DHEA/AI
and luteinizing hormone (LH)>, < androgens/T/ASD/
DHEA/AI and follicle stimulating hormone (FSH)>, <
androgen receptors (AR) in folliculogenesis/follicle
maturation/oocyte maturation>.
Relevant manuscripts were identified and their refer-
ence lists reviewed for additional references, which
either were not discovered through above described lit-
erature search or preceded the search period. Combined,
this resulted in an initial review of 217 publications.
Since the review by Laufer, published in 2009, covered
the subject well up to 2007 (58/60 references were pre-
2007) [9], we concentrated on manuscripts published
after 2007, listing here 101 references.
Animal models
The most profound changes in understanding effects of
androgens on folliculogenesis come from in vivo animal
data, in vitro follicle culture bioassays, and studies invol-
ving the AR. Androgens primarily exert effects through
transcriptional regulation by the nuclear AR [10].
Increasing evidence, however, now also points towards
non-genomic androgen signaling [7,11,12].
Effects of androgens on the ovary
As summarized by Lenie and Smitz [10], androgens at
sub-nanomolar concentrations exert genomic and non-
genomic effects. As a ligand-activated transcription fac-
tor, AR detects sub-nanomolar androgens in cytoplasm,
and converts androgen signals into changes in gene
expression [13]. Rapid non-genomic signaling of andro-
gens, ultimately, may modulate transcriptional activities
of AR. They also note that, amongst the various ovarian
cell types, most AR expression can be found in granu-
losa cells.
Androgens affect follicle maturation from very early
stages on: In bovine follicles Yang and Fortune reported
T to stimulate transition from primary to secondary fol-
licle [14]. Relevant to the clinical human experience, in
rodents and primates Ar mRNA and AR protein appear
in highest concentrations in ovaries containing mostly
immature preantral and early antral follicles. Ar mRNA
and AR protein then decrease with advancing follicle
maturation [15-17], suggesting a primary importance for
androgens especially in early stages of follicle maturation
(Figure 1).
Preantral and early antral follicles constitute a majority
of what we in clinical practice have come to call
functional ovarian reserve (FOR), best assessed by anti-
Müllerian hormone (AMH) and antral follicle count
(AFC) [18]. Positive and/or negative effects of androgens
should, therefore, be reflected in AMH levels and AFCs
(see also later).
Not all androgens are equally agonistic for the AR. T
and its metabolite 5a-dihydrotestosterone (DHT) are
the most potent naturally occurring agonists [10]. Ovar-
ies and adrenals produce three distinct androgens dur-
ing steroidogenesis: ASD, T and DHEA. Since their
agonism with AR differs, varying effects of androgens
appear likely (see also later). Moreover, one also has to
consider the possibility that metabolites of these andro-
gens exert effects, possibly via different mechanisms
and/or receptors. Estrogenic effects via estrogen recep-
tors are a possible example.
Lutz et al reported that only T and ASD potently
induced oocyte maturation in Xenopus, whereas DHT
actually inhibited T- and human chorionic gonadotropin
(hCG)-induced maturation and signaling [11]. Differ-
ences in reported clinical androgen effects may, there-
fore, also be consequence of varying agonistic AR
effectsby different androgens.
Whichever androgens induce ligand-activated AR, all
potentially modulate FSH activities in developing granu-
losa cells. They, therefore, serve as important modula-
tors of granulosa cell differentiation and follicle
maturation, especially during particularly FSH-depen-
dent, early antral stages [10]. As already noted earlier,
androgenic effects on follicle maturation, therefore,
appear especially pronounced at these early stages of fol-
liculogenesis (Figure 1).
Interactions between ligand-activated AR and FSH can,
thus, be viewed as a form of synergistic “feed back” since
granulosa cells respond to FSH at those stages of develop-
ment with changes in androgen metabolism. This happens
due to changes in expression in steroidogenic enzymes
P450scc, P450arom, and 5a-reductase, in turn determin-
ing type of androgen and relative distribution of the three
main androgens in follicles [10]. These androgens, in turn,
as noted previously, can affect the developing follicle in
genomic (AR) and non-genomic ways (diffusion, etc).
Clinically, one, therefore, would expect synergistic effects
of androgens and FSH at these stages of follicle maturation
(to be further discussed later, and Figure 1).
Lenie and Smitz demonstrated in a mouse in vitro fol-
liculogenesis model the importance of AR to normal fol-
licle maturation. By treating follicles with anti-
androgenic compounds, follicle growth during the pre-
antral phase was reduced, the steroidogenic environ-
ment was altered, and, probably most importantly,
oocyte meiotic maturation in response to human hCG
was arrested [10]. Androgen receptor knock out
(ARKO) models provide further clarity.
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Walters et al recently summarized how ARKO mouse
models are able to decipher AR-mediated female repro-
ductive functions [19]. AR is expressed in various repro-
ductive tissues, including, as noted, in different ovarian
cells and neuroendocrine tissues, like pituitary and
hypothalamus [20]. Sen and Hammes recently elegantly
elucidated AR effects in different organs/tissues by gen-
erating granulosa cell- and oocyte-specific ARKO mice,
allowing determination of where androgen-dependent
effects were located [21]: Almost all reproductive pheno-
types observed in global ARKO mice proved explainable
by AR expressions in granulosa cells, including prema-
ture ovarian failure (POF), subfertility with longer
estrous cycles and fewer ovulated oocytes, more prean-
tral and atretic follicles, fewer antral follicles and fewer
corpora lutea. In addition, in vitro growth of follicles
was slower than in control wild-type animals.
Oocyte-specific ARKO mice, in contrast, demonstrated
none of these phenotypes, and androgens no longer pro-
moted oocyte maturation. ARKO mice, due to disrup-
tions in AR signaling, also exhibited altered uterine
development, though not reduced fertility [21]. Fertility
impairment in ARKO mice appears, thus, primarily
ovarian in nature.
Oocytes, however, also appear to benefit from andro-
gen effects. Li et al reported that T positively contri-
butes to porcine oocyte meiotic resumption. AR
apparently significantly contributes to T-induced mito-
gen-activated protein kinase activation and germinal
vesicle breakdown [22].
Androgen production and therapeutic ranges
Theca cells provide all androgens required by develop-
ing follicles. They then are converted by granulosa cells
through the action of P450 aromatase into the
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Figure 1 Synergism between androgen and FSH. The figure depicts the potential synergism of androgens and follicle stimulating hormone
(FSH) during early folliculogenesis. Here in detail depicted only on pre-antral and early antral follicles, the figure is meant to demonstrate the
high concentration of androgen receptor (AR) at pre-antral to antral stages, declining thereafter [10,15-17]. High concentrations of AR at these
stages are strongly suggestive of peak androgen effects at these stages of folliculogenesis. Androgens primarily affect granulosa cells [21]
through transcriptional regulation via AR but do so also via non-genomic ways, with ligand-activated AR modulating FSH activity in granulosa
cells. The box in the right lower quadrant schematically demonstrates the synergism between androgens and FSH, based on Lenie and Smitz
[10], practically creating a feed back loop.Synergism between androgens and FSH suggests the possibility of new pharmacologic approaches to
ovulation induction, utilizing this synergism in early folliculogegesis to improve oocyte numbesr and quality. For further detail, see text.
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tion, androgens may, thus, also exert effects through the
estrogen receptor.
In gonadotropin-dependent stages of folliculogenesis,
androgen production is controlled by luteinizing hor-
mone (LH) [24]. In vitro culture of theca cells also
results in androgen production with low level LH stimu-
lation; but under high level LH, ASD production is
inhibited and progesterone secretion is stimulated, sug-
gesting luteinization of theca cells [25].
Applying this clinically, Shoham suggested a “thera-
peutic window” range for LH [26], and we proposed
relative therapeutic ranges for all hormones, based on
in-range agonist/antagonist ratios rather than specific
hormone levels [27]. Romero and Smitz recently, indeed,
demonstrated a therapeutic range for androgens in
mouse ovarian follicles [6].
In an in vitro follicle bioassay they investigated exo-
genous addition of ASD and T. Both androgens altered
endogenous production of ASD, T, estradiol and proges-
terone, and affected oocyte capacity to resume meiosis.
ASD at concentrations above 200 nM induced increased
T and estradiol production. Exposure to T above 200
nM induced, however, elevated levels of estradiol and
progesterone, while exposure to ASD, as well as T, at
those concentrations demonstrated dose-dependent
negative effects on polar body extrusion. ASD-treated
follicles, in addition, also produced oocytes with chro-
mosome displacements on the metaphase plate, while
follicles exposed to 25 mIU/mL FSH, 3 mIU/mL hCG
and elevated aromatizable androgens altered steroid pro-
files, and demonstrated abnormal follicle development as
well as impaired oocyte meiotic competence.
Using rat granulosa cells, Wu et al recently demon-
strated that T in absence of gonadotropins increases
aromatase (Cyp19) and P450scc side-change cleavage
expression, both enzymes of major importance for nor-
mal ovarian function. Cyp19 converts T into estradiol,
while 5a-reductase converts it into the pure androgen
5a- DHT [28]. They also demonstrated in this study
that T directly affects the expression of genes involved
in granulosa cell differentiation.
How sensitive the developing follicle is to fluctuations
in hormone substrates was recently also demonstrated
by Sánchez et al, who reported that FSH concentrations
alter gene expression in the cumulus-oocyte complex in
mice. Even as small as a 2.5-fold increase in FSH chan-
ged oocyte and cumulus cell transcript levels. Decreas-
ing FSH levels did not change transcript levels but
limited inappropriate luteinizing hormone/chorionic
gonadotropin receptor (Lhcgr) expression [29], a finding
potentially relevant to the discussion about clinical
effects of higher versus lower gonadotropin dosages dur-
ing ovulation induction.
Like other hormones, androgens, thus, apparently
function within therapeutic ranges, but vary in their
effects on follicle and oocyte even at similar concentra-
tions. Both of these observations can, at least partially,
explain the many contradictory reports of androgen
effects in female infertility. Table 1 summarizes hormo-
nal ovarian effects of androgens in various animal
models.
In addition to endocrine effects, androgens also exert
immune effects with significance on ovarian function. Si
et al reported in a mouse model that glucocorticoids
and androgens equally ameliorate POF [30]. Since auto-
immunity appears increased in infertile women [31],
androgens may also beneficially affect ovarian function
by serving as antagonists towards strong female autoim-
mune predisposition [32], which quite often is directed
against the ovary [33].
Human Data
As noted, androgens have mostly been considered clini-
cally detrimental to follicle development. Aside from
early animal data [1-4], this was mostly due to the
hyperandrogenism observed in many classical PCOS
patients, associated with anovulation and inferior oocyte
quality in IVF [5]. PCOS, therefore, represents a good
starting point for a review of human data.
PCOS as a model of androgen excess
Qiao and Feng recently described hyperandrogenemia as
one of the “intra-ovarian” factors characterizing PCOS
and affecting oocyte maturation. They note that hyper-
androgenemia is typically attributed to excessive andro-
gen production by ovaries, with substantial contribution
from adrenals and, to a lesser extent, from adipose tis-
sue. High androgen levels in women with insulin resis-
tance can also be due to inhibition of hepatic
production of sex hormone-binding globulin (SHBG)
[5].
Also according to these authors, studies suggest
adverse effects of high androgen levels on oocyte devel-
opmental competence [34-36]. Typically, small PCOS
follicles are hyperandrogenic due to raised androgen
production by theca cells [37,38].
PCOS is a heterogeneous ovarian syndrome, charac-
terized by a multitude of reproductive-endocrine as well
as metabolic phenotypes [5]. One, however, also could
argue that polycystic ovaries, themselves, represent an
ovarian phenotype, shared by hyperandrogenic and
n o r m o - a n d r o g e n i cf e m a l e s .S i n c eo n l ys o m eP C O S
patients are hyperandrogenic, hyperandrogenemia can-
not be the only etiology of PCOS [5].
Because of the heterogeneity of PCOS patients, it is
difficult to interpret published outcome data after infer-
tility treatments. Since large numbers of very small
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diagnosis, it is not surprising that, independent of
underlying etiology, all PCOS patients characteristically
produce large oocyte yields after gonadotropin stimula-
tion [39]. Some authors have suggested, though, that
oocyte quality lags, resulting in lower implantation, and
higher miscarriage rates as well as more aneuploidy
[40,41]. Others reported no meaningful outcome differ-
ences between PCOS and control patients in IVF cycles
[42,43]. Weghofer et al determined that, over all, PCOS
patients produce larger euploid embryo numbers, yet
still demonstrate lower pregnancy and higher miscar-
riage rates [44], suggestive of a non-chromosomal qual-
ity factor in oocytes.
Differences in reported outcomes most likely are a
consequence of noted etiological heterogeneities. This is
supported by our recent report of an ovarian PCOS
phenotype, highly associated with a specific FMR1 sub-
genotype (het-norm/low), neither associated with obesity
nor hyperandrogenism but with rapidly depleting ovar-
ian reserve. Affected women at young ages demonstrate
classical PCOS but at mid- and older ages often exhibit
abnormally diminished FOR [33]. The PCOS phenotype
i s ,t h e r e f o r e ,n o ts t a b l ep r esence in all PCOS patients,
and can disappear.
Some animal data are relevant to a better understand-
ing of PCOS in humans: For example, it has been
known for some time that in animal models dehydroe-
piandrosteron (DHEA) can induce PCOS phenotypes in
previously normal ovaries [45,46]. In humans we
demonstrated the same only more recently, when long-
term DHEA supplementation, in women with even very
severe DOR was shown to result in typical PCOS-like
ovaries [47] (for further detail, see below).
Increased T and/or LH levels in women with PCOS
have been widely associated with elevated AMH levels,
and have been suggested as causes of impaired follicle/
oocyte development and embryo quality [38,48,49]. High
serum AMH levels, however, do not necessarily indicate
high intrafollicle AMH levels. We, for example, demon-
strated that AMH per oocyte retrieved varies based on
FMR1 genotypes and sub-genotypes [50]. Whether
intrafollicle AMH levels reflect the quality of follicle
maturation has, indeed, remained highly contested.
Probably as many investigators concluded that high
intrafollicle AMH in PCOS patients is harmful, as have
reached the opposite conclusion [5].
Currently the only X-linked candidate gene for PCOS
is the AR gene [51]. The gene’s CAG repeat polymorph-
ism has been reported associated with a PCOS pheno-
type [52]. As Van Nieuwerburgh et al recently reported,
shorter CAG repeats in the AR gene appear to enhance
androgenicity in PCOS. Specifically, PCOS patients with
bi-allelic means of less than 21 repeats had lower DHT,
ASD, LH levels, LH/FSH ratios and more clinical signs
of hyperandrogenism, like acne and hirsutism. Most
other authors were, however, unable to confirm such
associations [53-55].
Such opposing conclusions may, once again, be a con-
sequence of patient selection, reflective of different
underlying PCOS pathophysiologies, and, perhaps, geno-
types. The prevalence of polymorphisms may, however,
also differ based on racial/ethnic backgrounds of study
populations, as recently demonstrated with CGG repeat
polymorphisms in the FMR1 gene [56]. Dasgupta et al,
studying South Indian women, concluded that CAG
repeat polymorphism, by itself, does not represent a use-
ful marker of PCOS. They, however, noted among
PCOS patients a trend towards preferential activation of
shorter alleles (among individuals with non-random X-
inactivation) [57].
Returning to animal models, a causal relationship
between hyperandrogenism and PCOS is also suggested
by Yang et al [58], who tried to elucidate the molecular
mechanisms of excessive androgens in a mouse PCOS
model. Culturing neonatal mouse ovaries with T, mainly
containing primordial follicles, they demonstrated
increases in primary follicles via the phosphatidylinositol
Table 1 Summary of androgen effects on maturing follicles based on animal data
Observation Potential clinical relevance
Different androgens affect ovarian follicles in varying
ways
May explain positive and negative effects reported in literature; Different androgens can be
expected to have different clinical effects.
Androgens will affect follicles differently at varying
concentrations
Same as above
Androgens affect ovaries through genomic (AR) and
non-genomic signaling
￿ Most affected cell type: granulosa cells Granulosa cell abnormalities should be associated with POF and other ovarian function
abnormalities
￿ Most affected maturation stage: preantral and early
antral follicles
Androgen effects should be visible in AMH levels and AFCs
Androgens activate FSH activity on granulosa cells
the most at antral stage
Antral stage should be most responsive to synergistic activity of androgens and FSH
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androgens induced Forkhead box (Foxo)-3a activation,
and translocation of Foxo3a protein from oocyte nuclei
to the cytoplasm, likely a key step in the activation of
primordial follicles. That T may, indeed, enhance follicle
recruitment in PCOS, has previously already been sug-
gested by Qureshi et al [59].
T was, however, also able to down-regulate the
expression of growth and differentiation of factor-9
expression via its receptor, and, therefore, can in this
mouse PCOS model induce arrest of follicle develop-
m e n t[ 5 8 ] .T ,t h u s ,i nt h i sm o d e la p p e a r sa b l et o
improve recruitment of resting primordial follicles but
also potentially contributes to arrest of developing folli-
cles. Looking at T in its potential clinical utility, T, thus,
once again, appears able to exert positive and negative
effects on follicle maturation.
PCOS data from animal models, therefore, contribute
two important facts of potential clinical relevance to
humans: Androgens appear to enhance follicle recruit-
ment, and, potentially, can have positive as well as nega-
tive effects on follicle maturation; not only, as still
widely believed, negative ones.
Heterogeneity of PCOS phenotypes in humans, likely,
is the principal reasons why these opposing effects, so
far, have not been yet isolated, which in clinical practice
would make them better targets for individualized thera-
peutic interventions.
DHEA in human subfertility
Within such a context it is noteworthy that DHEA has
found increasing clinical application in the treatment of
diminished ovarian reserve, recently reviewed in detail
elsewhere [60].
Once again briefly returning to the mouse, we pre-
v i o u s l yn o t e dt h a taD H E A - i n d u c e dm o u s em o d e lo f
PCOS has been utilized in a variety of research disci-
plines [45,46]. It was actually first reported in the rat by
Lee et al [61], and only later applied to mouse experi-
ments [45,46,62,63].
Belgorosky et al replicated some of the above-dis-
cussed T-induced observation with DHEA in the mouse,
demonstrating increased growth rate of primary follicles.
Yet, DHEA also increased oxidative stress, and
decreased the number of viable ovarian cells, while
increasing early apoptotic cells [62]. The same group
later further defined DHEA effects in the mouse ovary
[63], demonstrating that, like T, DHEA potentially
induces clinically beneficial and detrimental effects on
follicle maturation.
These authors also demonstrated distinct immunolo-
gic DHEA effects on the ovary: DHEA-induced hyperan-
drogenism increased T lymphocytes in ovarian tissue,
modifying the phenotype by decreasing helper T cells
(CD4
+) and decreasing suppressor/cytotoxic T cell (CD8
+)
[62]. Luchetti et al [45] and Sander et al [46] had pre-
viously reported similar immune effects of DHEA, the lat-
ter group also demonstrating increases in serum tumor
necrosis factor-alpha (TNF-a). CD4
+/CD8
+ cells and
TNF-a are, of course, intimately involved with autoimmu-
nity [64,65], a potentially important observation, consider-
ing suggested antagonistic activities of androgens in
regards to the excessive autoimmune risk of women [32].
Existence of a DHEA-induced animal model for PCOS
[45,46,61,62], quite surprisingly, for the longest time did
not initiate human investigations of DHEA as an enhan-
cing agent in ovarian stimulation. When Casson et al
did investigate DHEA in so-called poor responders [66],
they were not motivated by an almost 20 years earlier
described rat model [61] but by the observation that
DHEA increases IGF-1 [67]. Though they reported mild
improvements in oocyte yield after short-term DHEA
supplementation [66], they did not further pursue the
clinical use of DHEA, failing to recognize its potential
clinical importance.
This was left to a series of studies pursued at our cen-
ter [47,68,69]. Here, correlations to above described
mouse model of DHEA were almost startling, when a
43 year old woman with severe DOR, supplemented
with DHEA over almost one year (and 9 IVF cycles),
developed ovaries with distinctive PCOS phenotype,
requiring declining gonadotropin dosages for fear of
ovarian hyperstimulation [47].
After self-administering DHEA during sequential IVF
cycles, she, since, has been acknowledged as the initiator
of worldwide DHEA research [60]. For details on the
utilization of DHEA in women with DOR the reader is
referred to a recent review, also listing relevant refer-
ences not included here [60]. Reported data, so far, sug-
gest that DHEA supplementation in women with DOR
improves oocyte and embryo yields, oocyte and embryo
quality, spontaneous and IVF pregnancy rates and
reduces embryo aneuploidy as well as miscarriage rates.
Published DHEA data were initially received with
skepticism because all but one small study [70] pub-
lished so far were neither blinded nor randomized and,
therefore, subject to significant potential biases. Larger
scale prospectively randomized clinical trials in the U.S.
and in Europe had to be abandoned for lack of patient
recruitment, as women with severe DOR, understand-
ably, refused randomization [69]. Other clinical trials are
still in progress [60].
Viewing published clinical DHEA data with here
described animal data in mind, they, however, suddenly,
appear more credible: If androgens can beneficially
affect primordial follicle recruitment [15,58], why would
improving oocyte yields with long-term DHEA supple-
mentation surprise? If androgens can beneficially affect
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why would better egg and embryo quality surprise?
Indeed, wouldn’t one then also, as has been reported
[69], expect increasing DHEA benefits over a few
months of supplementation, as broader maturing follicle
cohorts get exposed to DHEA?
Furthermore, since small follicles are best assessed by
AMH, wouldn’t reported improvements in AMH levels
after DHEA supplementation [71] be exactly what one
expects? And if androgens beneficially affect meiotic
maturation [7] and resumption [22], why would
improved aneuploidy and miscarriage rates surprise?
More on this, though, below.
Other androgens in human subfertility
Laufer extensively covered until 2007 human androgen
experiences in women with DOR [9]. He concluded that
differences in patient selection criteria, types of andro-
gens used, varying treatment schedules and the obvious
scarcity of studies preclude definite conclusions. Based
on data from use of aromatase inhibitors (AI), however,
he suggested that promoting an androgen-rich follicle
environment may improve IVF outcomes in women
who, previously, have failed standard IVF protocols.
But even this minor conclusion needs to be viewed with
caution, as documented by Lossl and associates, who in an
initial publication reported beneficial effects of aromatase
inhibitors on embryo quality [72] but, two years later, in a
prospectively randomized study, failed to demonstrate
such benefits [73]. Considering earlier noted differences in
affinity of androgens to the AR [10], and evidence that the
same androgen, at different concentrations, may have dif-
ferent effects [6], contradictory conclusions should, how-
ever, not surprise. With T and DHT most agonistic for
AR [10], studies utilizing these two hormones would
appear of greatest clinical interest. Our literature search,
indeed, revealed additional studies of relevance:
Frattarelli and associates also reported contradictory
studies: In a first study they suggested that low T levels
(< 20 ng/dL) are associated with significantly decreased
pregnancy chances in IVF [74]. But two years later they
reported only an association between low T levels and
IVF stimulation parameters, though no longer with
pregnancy chances [75]. Utilizing transdermal T, Massin
et al reported no benefits [76], while Balash and associ-
ates reported improved ovarian gonadotropin responses
in two studies [77,78].
Sipe and Van Voorhis reported improved follicular
response of gonadotropin stimulation after T patch
administration in a single case of Kallmann’ss y n d r o m e
[79]. The same group, however, reported in a small pro-
spectively randomized, placebo-controlled cross-over
study no effects from short-term (12-day) transdermal T
supplementation [80].
In contrast, Hossein Rashidi et al noted that T on day
14 after embryo transfer is predictive of IVF pregnancy
chances [81], and Qin et al that basal T levels were pre-
dictive of number of large follicles on day of ovulation
induction, and of pregnancy in women with DOR but
not in women with normal ovarian reserve.
Basal T levels were in this study also associated with
length of gonadotropin stimulation and total gonadotro-
pin dosage, suggesting that low T appears associated
with DOR [82]. In concurrence, Kim et al reported in a
prospectively randomized study that transdermal T sup-
plementation by gel resulted in significantly lower total
gonadotropin dosages and stimulation length, signifi-
cantly higher oocyte yields, more mature oocytes, more
fertilized oocytes, more good quality embryos, and
higher implantation as well as clinical pregnancy rates
[83].
Most recently published data, thus, appear supportive
of beneficial effects of T on ovarian response in women
with DOR. Quin et al with their study offer yet another
explanation for contradictory reports in the literature
[82]: By demonstrating a possible association between
low T levels and DOR, they suggest that primarily
patients with low androgen levels may benefit from sup-
plementation. Indeed, absence of treatment effectiveness
in women with normal ovarian reserve suggests that
androgen supplementation may be most effective in
hypoandrogenic women with DOR.
Such conclusions would also be supported by the find-
ings of Hossein Rashidi et al [81] and, ultimately, by ear-
lier noted animal experiments in mice [10,15-18]. If
further confirmed, androgen deficiency, like previously
for decades androgen excess [84], has to be added as
possible cause of female infertility.
Synergism between androgens and gonadotropins
Various observations support direct synergism between
androgens and gonadotropins in the ovary. Li et al
recently reviewed this synergism to some degree by for-
mulating a new hypothesis, proposing that during evolu-
tion expression of AR progressively shifts from oocytes
to theca cells, only to, ultimately, completely disappear
in oocytes, eliminating in mammalian oocytes the non-
genomic androgen pathway, unlike in somatic cells, thus
replacing the function of androgens and ARs in promot-
ing meiotic maturation with gonadotropins [7].
They also note how elusive the role of androgens and
AR in the ovary has remained. In earlier studies they
had found that only AR in oocytes, though not in
somatic cells, can positively affect porcine oocyte
maturation [85]. This, however, represents a typical
amphibian rather than mammalian characteristic, with
the latter, instead, characterized by meiotic promoters
like FSH and LH [7]. They, therefore, suggest that
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gone a shift from dominance to cooperation with gona-
dotropins. As a consequence, in mammals, androgens
no longer “control” follicle maturation (a function
assumed by gonadotropins) but exert selective control,
primarily in earlier stages of follicle maturation.
The authors further suggest that AR in mammalian
oocytes may be unnecessary, even harmful, and
hypothesize that abundance of AR in granulosa, but also
theca, in preantral and antral follicles, previously noted
in our discussion of animal data [10,15-17], could pre-
vent excess androgen from entering the oocyte, thus
assuring normal follicle growth. Unnecessary androgens
under such a concept could, however, still enter the
oocyte, bind to remnant AR, triggering non-genomic
effects, and forming dysfunctional follicles if abnormal
communications exist between granulomas cells and
oocyte [7].
As noted before, androgens enhance FSH-driven gran-
ulosa cell differentiation and follicle development espe-
cially at antral stages [10,29]. Since this developmental
stage of the follicle also corresponds to highest AR con-
centrations in granulosa cells [10,15-17], it is reasonable
to assume that, if androgens exert beneficial effects on
follicle maturation, this must be the stage of maximal
beneficial androgen effects.
One, therefore, can also hypothesize that at this stage
external androgen supplementation may most benefit
from concomitant external FSH supplementation.
Furthermore, assuming a therapeutic range for andro-
gens, as previously discussed, then one also has to
assume a “fitting” FSH level to achieve maximal benefits
for granulosa cell differentiation and follicle develop-
ment at this stage. Indeed, one can even further specu-
late that failure to achieve such an androgen/FSH
balance may be detrimental to normal follicle develop-
ment. A natural balance between androgens and gona-
dotropins may, indeed, exist, based on the work of
Casson et al, who reported that ovarian hyperstimula-
tion augments adrenal dehydroepiandrosterone sulfate
secretion [86].
All of these considerations, therefore, suggest the
potential of a new therapeutic ovarian stimulation
approach in DOR, utilizing this synergism between
androgens and FSH, in long-term parallel supplementa-
tion of granulosa cells with androgen as well as FSH (Fig-
ure 1). The first patient supplemented with DHEA at our
center, indeed, underwent nine consecutive gonadotro-
pin-stimulated IVF cycles while on DHEA supplementa-
tion [47]. She has remained one of the most responsive
patients to DHEA we have seen in over seven years, was
one with the longest concomitant FSH supplementation,
and, thus, amongst the longest patients exposed to the
potential benefits of such synergism.
Patients undergoing a large number of consecutive
cycles are rare. We, however, have had the opportunity
to follow a small number of such patients. Our preli-
minary impression is that, especially in women with
very severe DOR, we see better oocyte yields and quality
with consecutive ovarian stimulation cycles, which allow
for a synergistic androgen/FSH effect (Gleicher N, Barad
DH, unpublished data). A more formal study is
underway.
If confirmed, one then also could expect better cumu-
lative pregnancy rates. This then would be potentially
support a radically new ovarian stimulation protocol in
women with DOR, utilizing, in combination, long- term
androgen and low dose gonadotropin support, after a
few weeks to months intermittently followed by high
dose gonadotropin stimulation episodes, potentially
resulting in egg retrieval. This kind of synergism
between androgens and FSH is also strongly supported
by animal data [87].
Arising concepts
Our DHEA supplementation experience in women with
very severe DOR (undetectable AMH to 0.3 ng/mL),
based on surprisingly good pregnancy and live birth
numbers [88,89], unexpectedly low miscarriage rates
[90] and reduced embryo aneuploidy [91], led us to con-
clude that existing concepts of ovarian aging require
reconsideration. Aging oocytes, simply, no longer appear
logical. We, instead, suggested that the unrecruited
oocyte at primordial follicle stage does not age. Instead,
it is the ovarian environments, where follicle maturation
takes place after recruitment that age. Consequently, the
poorer environment of older ovaries negatively affects
the maturation process of, initially perfectly healthy,
oocytes [92].
Here presented review of androgens is supportive of
such a modified concept of ovarian aging. The review
demonstrates that androgens, in contrast to long held
beliefs, are not always detrimental to follicle maturation,
and, within therapeutic ranges, indeed, can be clinically
beneficial. Published data on the subject have for a vari-
ety of reasons been inconsistent (Table 2). As here pre-
sented, it is apparent that follicles are subject to
androgen effects from the earliest maturation stages on,
likely including recruitment, reaching peak intensity at
preantral and antral stages, androgens primarily affect
granulosa cells, inducing ligand-activated AR, which in
turn modulates FSH action in developing granulosa
cells, modulating differentiation and, consequently, folli-
cle development (10 and Figure 1).
As ovaries age, it is reasonable to assume that, like in
other organs, tissue processes decline in efficacy. For
example, DHEA levels significantly decrease with advan-
cing age [93], probably mostly the result of changes in
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increase but sex hormone-binding globulin decreases
[94], while FSH, of course, increases [95]. It, therefore,
appears very likely that androgenic follicle environments,
in which oocytes mature, change as women age. And so
do, of course, as a consequence, androgen/FSH ratios, as
previously noted synergistically acting on granulosa cells
(Figure 1).
These are likely, only two amongst many more,
adverse ovarian consequences due to older age. They,
however, at least partially can be reversed via androgen
supplementation, whether in form of DHEA, T or of
other androgens. The importance of normal androgen
levels, likely in a certain ratio to FSH levels, especially at
preantral and antral follicle stages, therefore, appears
obvious.
We noted before that based on varying degrees of
agonism with AR, different androgens exert varying
effects [10]. They, however, also affect ovarian processes
in non-genomic ways, adding additional potential varia-
bility [10,13]. For example, we recently reported that
more androgenic progestational agents in oral contra-
ceptives suppress ovarian reserve more severely than
less androgenic compounds [96], reemphasizing not
only the variability of androgenic ovarian effects but
their, at times, outright opposing effects. Some improve
[71], and others suppress FOR [96].
Clinical research over the last half century almost
exclusively concentrated on the last two weeks of follicle
maturation, the gonadotropin-sensitive phase of follicu-
logenesis. Here reviewed from a clinical vantage point,
androgen effects on follicle maturation may not only be
relevant for DOR patients but may offer the far larger
potential of a revolutionary new approach towards ther-
apeutic follicle maturation at much earlier stages of
folliculogenesis.
Such early therapeutic interventions into follicle
maturation will, however, only be successful if, as we
suggested [92], oocytes do not age as long as
unrecruited. Oocyte aging at primordial stage, tradition-
ally held responsible for declining fecundity and increas-
ing aneuploidy with advancing female age [97,98], would
render subsequent therapeutic interventions futile since
already damaged oocytes, even with treatment, cannot
be expected to recover [92].
Only assumption of undamaged, perpetually “young”
oocytes at time of recruitment allows for successful
therapeutic interventions post-recruitment, improving
the ovarian environment and,t h e r e f o r e ,t h eq u a l i t yo f
oocyte maturation, in turn leading to better oocyte and
embryo quality.
Such a concept is not entirely new: Hodges et al sug-
gested almost 10 years ago that treatments with poten-
tial to reduce age-associated aneuploidy by beneficially
influencing meiotic chromosome segregation may
become possible. They consider congression failure (dis-
turbances in chromosome alignment of meiotic spin-
dles) responsible for aneuploidy, and believe that a
variety of signals regulating folliculogenesis, together
with increased risk of non-disjunction errors, can be
therapeutically affected [99].
Androgens may be a first class of agents that do
exactly that! After all, androgens (in combination with
FSH) stimulate resumption of meiosis in ovaries and
testes, while AR gene inactivation blocks the effect
[7,10,19,22,100].
Romero and Smitz demonstrated that, at certain con-
centrations, ASD-treated follicles in vitro produce
oocytes with chromosome displacements on metaphase
plate [6]. Androgens, therefore, may very well affect
ploidy in oocytes. Some, like DHEA in humans, may
reduce aneuploidy [91] and others may, potentially,
exert opposite effects.
But not only androgens may beneficially affect early
stages of follicle maturation. Since in practically all tis-
sues mitochondrial functions are lost with advancing
age, Bentov et al proposed in women with DOR treat-
ment with mitochondrial nutrients [101].
In a mouse model such treatment proved effective
[102]. Treatment of DOR with androgens may, there-
fore, only a first step in improving the ovarian environ-
ment in which follicles mature.
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Gleicher et al. Reproductive Biology and Endocrinology 2011, 9:116
http://www.rbej.com/content/9/1/116
Page 9 of 12premature ovarian failure; SHBG: sex hormone-binding globulin; T:
testosterone; TNF: tumor necrosis factor
Acknowledgements
The study was supported y the Foundation for Reproductive Medicine and
intramural research funds from the Center for Human Reproduction, New
York.
Author details
1Center for Human Reproduction - New York, New York, USA.
2Foundation
for Reproductive Medicine, New York, New York, USA.
3Department of
Obstetrics, Gynecology and Reproductive Sciences, Yale University School of
Medicine, New Haven, Connecticut, USA.
4Department of Obstetrics and
Gynecology, Medical University Vienna, Vienna, Austria.
5Departments of
Epidemiology and Social Medicine and Obstetrics, Gynecology and Women’s
Health, Albert Einstein College of Medicine, Bronx, New York, USA.
Authors’ contributions
NG developed the concept for the study, reviewed all publication included
in the review of the literature and was the principal author of the
manuscript. DHB reviewed selected publications, contributed to design of
the study, was responsible for statistical considerations of the review and
contributed to the writing of the manuscript. AW contributed to the
concept of the study, and contributed to the writing of the manuscript. All
three authors approved the final version of the manuscript.
Competing interests
All three authors have in the past received research support, speakers’
honoraria and travel funds from various pharmaceutical and medical device
companies, none, however, related to the subject of this paper. N.G. and D.
H.B. are listed as co-inventors of an awarded U.S. patent, claiming
therapeutic benefits for DHEA, and potentially other androgens, in women
with diminished ovarian reserve. Both authors have other patent
applications, regarding DHEA, and potentially other androgens, and,
unrelated to this presentation, the FMR1 gene’s effects on ovaries, pending.
Received: 16 June 2011 Accepted: 17 August 2011
Published: 17 August 2011
References
1. Smith DM, Tenney DY: Effects of steroids on mouse oocyte maturation in
vitro. J Reprod Fertil 1980, 60:;331-338.
2. Eppig JJ, Freter RR, Ward Bailey PF, Schultz RM: Inhibition of oocyte
maturation in the mouse: participation of cAMP, steroid hormone, and a
putative maturation-inhibitory factor. Dev Biol 1983, 100:39-49.
3. Schultz RM, Montgomery RR, Ward-Bailey PF, Eppig JJ: Regulation of
oocyte maturatation in the mouse: possible roles of intercellular
communication, cAMP, and testosterone. Dev Biol 1983, 95:294-304.
4. Anderiesz C, Trounson AO: The effect of testosterone on the maturation
and development capacity of murine oocytes in vitro. Hum Reprod 1995,
10:2377-2381.
5. Qiao J, Feng HL: Extra- and intra-ovarian factors in polycystic ovary
syndrome: impact on oocyte maturation and embryo developmental
competence. Hum Reprod Update 2010, 17:17-33.
6. Romero S, Smitz J: Exposing cultured mouse ovarian follicles under
increased gonadotropin tonus to aromatizable androgens influences the
steroid balance and reduces oocyte meiotic capacity. Endocrine 2010,
38:243-253.
7. Li M, Schatten H, Sun Q-Y: Androgen receptor’s destiny in mammalian
oocytes: a new hypothesis. Molec Hum Reprod 2009, 15:149-154.
8. Kimura S, Matsumoto T, Matsuyama R, Shiina H, Sato T, Takeyama K, Kato S:
Androgen receptor function in folliculogenesis and its clinical
implication in premature ovarian failure. Trends Endocrinol Metab 2007,
18:183-189.
9. Laufer N: Role of androgens in the treatment of patients with low
ovarian response. Reprod Biomed Online 2009, 19:888-898.
10. Lenie S, Smitz J: Functional AR signaling is evident in an in vitro mouse
follicle culture bioassay that encompasses most stages of
folliculogenesis. Biol Reprod 2009, 80:685-695.
11. Lutz LB, Jamnongjit M, Yang W-H, Jahani D, Gill A, Hammes SR: Selective
modulation of genomic and nongenomic androgen responses by
androgen receptor ligands. Mol Endocrinol 2003, 17:1106-1116.
12. White SN, Jamnongjit M, Gill A, Lutz LB, Hammes SR: Specific modulation
of nongenomic androgen signaling in the ovary. Steroids 2005,
70:352-360.
13. Gelmann EP: Molecular biology of the androgen receptor. J Clin Oncol
2002, 20:3001-3015.
14. Yang MY, Fortune JE: Testosterone stimulates the primary to secondary
follicle transition in bovine follicles in vitro. Biol Reprod 2006, 75:924-932.
15. Tetsuka M, Whitelaw PF, Bremner WJ, Millar MR, Smith CD, Hillier SG:
Developmental regulation of androgen receptor in rat ovary. J Endocrinol
1995, 145:535-543.
16. Hillier SG, Tetsuka M, Fraser HM: Androgen receptor function in
folliculogenesis and its clinical implication in premature ovarian failure.
Hum Reprod 1997, 12:107-111.
17. Weil SJ, Vendola K, Zhou J, Adesanya OO, Wang J, Okafor J, Bondy CA:
Androgen receptor gene expression in the primate ovary: cellular
localization, regulation, and functional correlations. J Clin Endocrinol
Metab 1998, 83:2479-2485.
18. Gleicher N, Weghofer A, Barad DH: Defining ovarian reserve to better
understand ovarian aging. Reprod Biol Endocrinol 2011, 9:23.
19. Walters KA, Simanainen U, Handelsman FJ: Molecular insights into
androgen actions in male and female reproductive function from
androgen receptor knockout models. Hum Reprod Update 2010,
16:543-558.
20. Walters KA, McTavish KJ, Seneviratne MG, Jimenez M, McMahon AC,
Allan CM, Salamonsen LA, Handelsman DJ: Subfertile female androgen
receptor knockout mice exhibit defects in neuroendocrine signaling,
intraovarian function, and uterine development but not uterine
function. Endocrinology 2009, 150:3274-3282.
21. Sen A, Hammes SR: Granulosa-cell specific androgen receptors are critical
regulators of ovarian development and function. Mol Endocrinol 2010,
24:1393-1403.
22. Li M, Ai J-S, Xu B-Z, Xiong B, Yin S, Lin S-L, Hou Y, Chen D-Y, Schatten H,
Sun Q-Y: Testosterone potentially triggers meiotic resumption by
activation of intra-oocyte SRC and MAPK in porcine oocytes. Biol Reprod
2008, 79:897-905.
23. Young JM, McNeilly AS: Theca: the forgotten cell of the ovarian follicle.
Reproduction 2010, 140:489-504.
24. Palermo R: Differential actions of FSH and LH during folliculogenesis.
Reprod Biomed Online 2007, 15:326-337.
25. Campbell BK, Baird DT, Webb R: Effects of dose of LH on androgen
production and luteinization of ovine theca cells cultured in serum-free
system. J Reprod Fertil 1998, 112:69-77.
26. Shoham Z: The clinical therapeutic window for luteinizing hormone in
controlled ovarian stimulation. Fertil Steril 2002, 77:1170-1177.
27. Weghofer A, Gleicher N: Ovarian function: a theory of relativity. Hum
Reprod 2009, 24:17-19.
28. Wu YG, Bennett J, Talla D, Stocco C: Testosterone, not 5{alpha}
dihydrotestosterone, stimulates LRH-1 leading to FSH-independnet
expression of Cyp 19 and P450scc in granulosa cells. Mol Endocrinol
2011, 25:656-658.
29. Sánchez F, Adriaenssens T, Romero S, Smitz J: Different follicle-stimulating
hormone exposure regimens during antral follicle growth alter gene
expression in the cumulus-oocyte complex in mice. Biol Reprod 2010,
83:514-524.
30. Shi X, Li N, Liao C, Shu Q, Zhu F: Glucocorticoid or androgen for
autoimmune premature ovary failure in mice. Zhong Nan Da Xue Xue Bao
Yi Xue Ban 2009, 34:576-581.
31. Geva E, Amit A, Lerner-Geva L, Lessing JB: Autoimmunity and
reproduction. Fertil Steril 1997, 67:599-611.
32. Gleicher N, Barad DH: Gender as a risk factor for autoimmune diseases. J
Autoimmun 2007, 28:1-6.
33. Gleicher N, Weghofer A, Lee IH, Barad DH: FMR1 genotype with
autoimmunity-associated polycystic ovary-like phenotype and decrease
pregnancy chance. PLoS ONE 2010, 5:(12): e15303.
34. Brzynski RG, Grow DR, Smith JA, Seltman HJ: Increase in androgen:
estrogen ratio specifically during low dose follicle-stimulating hormone
therapy for polycystic ovary syndrome. Fertil Steril 1995, 64:693-697.
Gleicher et al. Reproductive Biology and Endocrinology 2011, 9:116
http://www.rbej.com/content/9/1/116
Page 10 of 1235. Teissier MP, Chable H, Paulhac S, Aubard Y: Comparison of follicle
steroidogenesis from normal and polycystic ovaries in women
undergoing IVF: relationship between steroid concentrations, follicle
size, oocyte quality and fecundability. Hum Reprod 2000, 15:;2471-2477.
36. Jabara S, Coutifaris C: In vitro fertilization in the PCOS patient: clinical
considerations. Semin Reprod Med 2003, 21:317-324.
37. Nelson VL, Qin K, Rosenfield RL, Wood JR, Penning JMTM, Legro RS,
Strauss JF, Mc Allister JM: The biochemical basis for increased
testosterone production in theca calls propagated from patients with
polycystic ovary syndrome. J Clin Endocrinol Metab 2001, 86:5925-5933.
38. Dumesic DA, Padmanabhan V, Abbott DH: Polycystic ovary syndrome and
oocyte development competence. Obstet Gynecol Surv 2007, 63:39-48.
39. Boomsma CM, Fauser BCJM, Macklon NS: Pregnancy complications in
women with polycystic ovary syndrome. Semin Reprod Med 2008,
26:72-84.
40. Heijnen EM, Eijkemans MJ, Hughes EG, Laven JS, Macklon NS, Fauser BC: A
meta-analysis of outcomes of conventional IVF in women with
polycystic ovary syndrome. Hum Reprod Update 2006, 12:13-21.
41. Sahu B, Ozturk O, Ranierri M, Serhal P: Comparison of oocyte quality and
intracytoplasmic sperm injection outcome in women with isolated
polycystic ovaries or polycystic ovarian syndrome. Arch Gynecol Obstet
2008, 277:239-244.
42. Kuivasaari-Pirinen P, Hippeläinen M, Hakkarainen H, Randell K, Heinonen S:
Cumulative baby take-home rate among women with PCOS treated by
IVF. Gynecol Endocrinol 2010, 26:582-589.
43. Nejad ES, Saedi T, Saedi S, Rashidi BH, Nekoo ZA, Jahangiri N: Comparison
of in vitro fertilsation success in patients with Polycystic ovary syndrome
and tubal factor. Gynecol Endocrinol 2011, 27:117-120.
44. Weghofer A, Munné S, Chen S, Barad D, Gleicher N: Lack of association
between polycystic ovary syndrome and embryonic aneuploidy. Fertil
Steril 2007, 88:900-905.
45. Luchetti CG, Solano ME, Sander V, Arcos ML, Gonzalez C, Di Girolamo G,
Chiocchio S, Cremaschi G, Motta AB: Effects of dehydroepiandrosterone
on ovarian cystogenesis and immune function. J Reprod Immunol 2004,
64:59-74.
46. Sander V, Lucchetti CG, Solano ME, Elia E, Di Girolamo G, Gonzalez C,
Motta AB: Role of the N,N’-dimethylbiguanide metformin in the
treatment of female prepuberal BALB/c mice hyperandrogenized with
dehydroepiandrosterone. Reproduction 2006, 131:591-602.
47. Barad DH, Gleicher N: Increased oocyte production after treatment with
dehydroepiandrosterone. Fertil Steril 2005, 84:756.
48. Franks S, Stark J, Hardy K: Follicle dynamics and anovulation in polycystic
ovary syndrome. Hum Reprod Update 2008, 14:367-368.
49. Patel SS, Carr BR: Oocyte quality in adult polycystic ovary syndrome.
Semin Reprod Med 2008, 26:196-203.
50. Barad DH, Kim A: Correlation between functional ovarian reserve,
assessed by anti-Müllerian hormone (AMH), and oocyte numbers, based
on FMR1 genotypes and sub-genotypes: The hom sub-genotypes. Fertil
Steril , (ASRM Suppl); submitted.
51. Zhu J-Q, Zhu L, Liang X-W, Xing F-Q, Schatten H, Sun Q-Y: Demetyhylation
of LHR in dehydroepiandrosterone-induced mouse model of polycystic
ovary syndrome. Molec Hum Reprod 2010, 16:260-266.
52. Van Nieuwerburgh F, Stoop D, Cabri P, Dhont M, Deforce D, De Sutter P:
Shorter CAG repeats in the androgen receptor gene may enhance
hyperandrogenicity in polycystic ovary syndrome. Gynecol Endocrinol
2008, 24:669-673.
53. Liu H, Hong J, Cui B, Zhang Y, Gu W, Chi Z, Su Y, Ning G: Androgen
receptor gene CAG(n) trinucleotide repeats polymorphism in Chinese
women with polycystic ovary syndrome. Endocrine 2008, 33:165-170.
54. Jääskeläinen J, Korhonen S, Kuulasmaa T, Kurl S, Niskanen L, Vanhala M,
Hippeläinen M, Voutilainen R, Heinonen S: Androgen receptor gene CAG
repeat length in women with metabolic syndrome. Gynecol Endocrinol
2008, 24:411-416.
55. Ferk P, Perme MP, Teran N, Gersak K: Androgen receptor gene (CAG)n
polymorphism in patients with polycystic ovary syndrome. Fertil Steril
2008, 90:860-863.
56. Gleicher N, Weghofer A, Lee IH, Barad DH: Association of FMR1 genotypes
with in vitro fertilization (IVF) outcomes based on ethnicity/race. PLoS
ONE 6(4):e18781.
57. Dasgupta S, Sirisha PVS, Neelaveni K, Anuradha K, Reddy AG, Thangaraj K,
Reddy BM: Androgen receptor CAG repeat polymorphism and epigenetic
influence among the South Indian Women with polycystic ovary
syndrome. PLoS ONE 5(8):e12401.
58. Yang J-L, Zhang C-P, Li L, Huang L, Ji S-Y, Lu C-L, Fan C-H, Cai H, Ren Y,
Hu Z-Y, Gao F, Liu Y-X: Testosterone induces redistribution of Forkhead
box-3a and down regulation of growth and differentiation factor 9
messenger ribonucleic acid expression at early stage of mouse
folliculogenesis. Endocrinology 2010, 151:774-782.
59. Qureshi AI, Nussey SS, Bano G, Musonda P, Whitehead SA, Mason HD:
Testosterone selectively increases primary follicles in ovarian cortex
grafted onto embryonic chick membranes: relevance to polycystic
ovaries. Reproduction 2008, 136:187-194.
60. Gleicher N, Barad DH: Dehydroepiandrosterone (DHEA) supplementation
in diminished ovarian reserve (DOR). Reprod Biol Endocrin .
61. Lee MT, Anderson E, Lee GY: Changes in ovarian morphology and serum
hormones in the rat after treatment with dehydroepiandrosterone. Anat
Rec 1991, 231:185-192.
62. Belgorosky D, Sander VA, Yorio MP, Faletti AG, Motta AB:
Hyperandrogenism alters intraovarian parameters during early
folliculogenesis in mice. Reprod Biomed Online 2010, 20:797-807.
63. Elia E, Sander V, Luchetti CG, Solano ME, Di Girolamo G, Gonzalez C,
Motta AB: The mechanism involved in the action of metformin in
regulating ovarian function in hyperandrogenized mice. Molec Hum
Reprod 2006, 12:4750481.
64. Chang C, Gershwine ME: Drug-induced lupus erythematosus: incidence,
management and prevention. Drug Saf 2011, 34:357-374.
65. Chen X, Oppenheim JJ: Contrasting effects of TNF and anti-TNF on the
activation of effector T cells and regulatory T cells in autoimmunity. FEBS
Lett 2011.
66. Casson PR, Lindsay MS, Pisarska MD, carson SA, Buster JE:
Dehydroepiandrosterone aupplementation augments ovarian
stimulation in poor responders; a case series. Hum Reprod 2000,
15:2129-2132.
67. Casson PR, Santoro N, Elkind-Hirsch K, Carson SA, Hornsby PJ, Abraham G,
Buster JE: Postmenopausal DHEA administration increases free insulin-
like growth factor - I and decreases high-density lipoprotein: a six-
month trial. Fertil Steril 1998, 70:107-110.
68. Barad D, Gleicher N: Effect of dehydroepiandrosterone on oocyte and
embryo yields, embyo grade and cell number in IVF. Hum Reprod 2006,
21:2845-2849.
69. Barad DH, Brill H, Gleicher N: Update on the use of
dehydroepiandrosterone supplementation among women with
diminished ovarian function. J Assist Reprod Genet 2007, 24:629-634.
70. Wiser A, Gonen O, Ghetler Y, Shavit T, Berkovitz A, Shulman A: Addition of
dehydroepiandrosterone (DHEA) for poor-respoder patients before and
during IVF treatment improves the pregnancy rate: a randomized
prospective study. Hum Reprod 2010, 25:2496-2500.
71. Gleicher N, Weghofer A, Barad DH: Improvement in diminished ovarian
reserve after dehydroepiandrosterone supplementation. Reprod Biomed
Online 2010, 21:360-365.
72. Lossl K, Andersen AN, Loft A, Freisesleben NK, Bangsbøll S, Andersen CY:
Androgen priming using aromatase inhibitor and hCG during early-
follicular phase GnRH antagonist down-regulation in modified
antagonist protocol. Hum Reprod 2006, 21:2593-2600.
73. Lossl K, Andersen CY, Loft A, Freiesleben NL, Bangsbøll S, Andersen AN:
Short-term androgen priming with use of aromatase inhibitor and hCG
before controlled ovarian stimulation for IVF. A randomized controlled
trial. Hum Reprod 2008, 23:1820-1929.
74. Frattarelli JL, Peterson EH: Effect of androgen levels on in vitro
fertilization cycles. Fertil Steril 2004, 81:1713-1714.
75. Frattarelli JL, Gerber MD: Basal and cycle androgen levels correlate with
in vitro fertilization stimulation parameters but do not predict
pregnancy outcome. Fertil Steril 2006, 86:51-57.
76. Massin N, Cedrin-Durnerin I, Coussieu C, Galey-Fontaine J, Wolf JP,
Hugues JN: Effects of transdermal testosterone application on the
ovarian response to FSH in poor responders undergoing assisted
reproductive-technique - a prospective randomized, double blind study.
Hum Reprod 2006, 21:1204-1211.
77. Balasch J, Fábreques F, Peñarurubia J, Carmona F, Casamitjana R, Creus M,
Manau D, Casals G, Vanrell JA: Pretreatment with transdermal
testosterone may improve ovarian response to gonadothrophins in
Gleicher et al. Reproductive Biology and Endocrinology 2011, 9:116
http://www.rbej.com/content/9/1/116
Page 11 of 12poor-responder IVF patients with normal baseline concentration of FSH.
Hum Reprod 2006, 21:; 1884-1893.
78. Fábreques F, Peñarurubia J, Creus M, Manu D, Caals G, Carmone F,
Balasch J: Transdermal testosterone may improve ovarian response to
gonadotrophins in low-repsonder IVF patients: a randomized, clinical
trial. Hum Reprod 2009, 24:349-359.
79. Sipe CS, Van Voorhis BJ: Testosterone patch improves ovarian follicular
response to gonadotrophins in a patient with Kallmann’s syndrome: a
case report. Hum Reprod 2007, 22:1380-1383.
80. Sipe CS, Thomas MR, Stegman BJ, Van Voorhis BJ: Effects of exogenous
testosterone supplementation in gonadotrophin stimulated cycles. Hum
Reprod 2010, 25:690-696.
81. Hossein Rashidi B, Hormoz B, Shahrokh Tehraninejad E, Shariat M,
Mahdavi A: Testosterone and dehydroepiandrosterone sulfate levels and
IVF/ICSI results. Gynecol Endocrin 2009, 25:194-198.
82. Qin Y, Zhao Z, Sun M, Geng L, Che L, Chen Z-J: Association of basal serum
testosterone levels with ovarian response and in vitro fertilization
outcome. Reprod Biol Endocrin 2011, 9:9.
83. Kim C-H, Howles CM, Lee H-A: The effect of transdermal testosterone gel
pretreatment on controlled ovarian stimulation and IVF outcome in low
responders. Fertil Steril 2011, 95:679-683.
84. Homburg R: Androgen circle of polycystic ovary syndrome. Hum Reprod
2009, 24:1548-1555.
85. Li M, Ai JS, Xu BZ, Xiong B, Tin S, Lin SL, Hou Y, Chen DY, Schatten H,
Sun Qy: Testosterone potentially triggesr meiotic resumption by
avtivation of intra-oocyte SRC and MAPK in porcine oocyte. Domest Anim
Endocrinol 2008, 34:360-371.
86. Casson PR, Kristiansen SB, Umstot EE, Carson SA, Buster JE: Ovarian
hyperstimulation augments adrenal dehydroepiandrosterone sulfate
secretion. Fertil Steril 1996, 65:950-953.
87. Wang H, Andoh K, Hagiwara H, Xiaowei L, Kikuchi N, Abe Y, Yamada K,
Fatima R, Mizunuma H: Effect of adrenal and ovarian androgens on type
4 follicles unresponsive to FSH in immature mice. Endocrinol 2001,
142:4930-4936.
88. Gleicher N, Weghofer A, Barad DH: Anti-Müllerian hormone (AMH)
defines, independent of age, low versus good live birth chances in
women with severely diminished ovarian reserve. Fertil Steril 2010,
94:2824-2827.
89. Weghofer A, Dietrich W, Barad D, Gleicher N: Live birth chances in women
with extremely low serum anti-Müllerian hormone levels. Hum Reprod
2011.
90. Gleicher N, Ryan E, Weghofer A, Blanco-Meija S, Barad DH: Miscarriage
rates after dehydroepiandrosterone (DHEA) supplementation in women
with diminished ovarian reserve: a case control study. Reprod Biol
Endocinol 2009, 7:108.
91. Gleicher N, Weghofer A, Barad DH: Dehydroepiandrosterone (DHEA)
reduces embryo aneuploidy: direct evidence from preimplantation
genetic screening (PGS). Reprod Biol Endocrinol 2010, 8:140.
92. Gleicher N, Weghofer A, Barad DH: Defining ovarian reserve to better
understand ovarian aging. Reprod Biol Endocrinol 2011, 9:23.
93. Jacob MH, da R Janner D, Jahn MP, Kucharski LB, Belló-Klein A, Ribeiro MF:
Age-related effects of DHEA on peripheral makers of oxidative stress.
Cell Biochem Funct 2010, 28:52-57.
94. Sowers MFR, Zheng H, McConnell D, Nan B, Karvonen-Guiterez CA,
Randolph JF Jr: Testosterone, sex hormone-binding globulin and free
androgen index among adult women: chronological and ovarian aging.
Hum Reprod 2009, 24:2276-2285.
95. Barad DH, Weghofer A, Gleicher N: Age-specific levels of basal follicle-
stimulating hormone assessment of ovarian function. Obstet Gynecol
2007, 109:1404-1410.
96. Gleicher N, Kubba H, Weghofer A: Hormonal contraception prior to in
vitro fertilization (IVF) adversely affects functional ovarian reserve and
oocyte yields. Fertil Steril , (ASRM Suppl), submitted.
97. Coccia ME, Rizzello F: Ovarian reserve. An NY Acad Sci 2008, 1127:27-30.
98. Broekmans FJ, Soules MR, fauser BC: Ovarian aging: mechanisms and
clinical consequences. Endocr Rev 2009, 30:465-493.
99. Hodges CA, Ilagan A, Jenninger D, Keri R, Nilson J, Hunt PA: Experimental
evidence that changes in oocyte growth influence meiotic chromosome
segregation. Hum Reprod 2002, 17:1171-1180.
100. Sá R, Neves R, Fernandes S, Alves C, Carvalho F, Silva J:.
101. Bentov Y, Esfandiari N, Burstein E, Casper RF: The use of mitochondrial
nutrients to improve the outcome of infertility treatment in older
patients. Fertil Steril 2010, 93:272-275.
102. Malheiro I, Barros A, Sousa M: Cytological and expression studies and
quantitative analysis of the temporal and stage-specific effects of
follicle-stimulating hormone and testosterone during cocultures of the
normal human seminiferous epithelium. Biol Reprod 2008, 79:962-975.
doi:10.1186/1477-7827-9-116
Cite this article as: Gleicher et al.: The role of androgens in follicle
maturation and ovulation induction: friend or foe of infertility
treatment? Reproductive Biology and Endocrinology 2011 9:116.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Gleicher et al. Reproductive Biology and Endocrinology 2011, 9:116
http://www.rbej.com/content/9/1/116
Page 12 of 12